97% of patients meet the standard! Oral prostate cancer new drug reaches phase 3 main endpoint

Prostate cancer is the second most common cancer among men in the worldIt is estimated that 1.2 million new patients will be within written in 2018, while about 360,000 will die as a resultProstate cancer is the 5th leading cause of cancer death in menFor patients with destenating-sensitive prostate cancer, standard treatments include the gonadotropin-releasing hormone (GnRH) agonist, leuprolide acetateHowever, this treatment may cause a short-lived increase in testosterone levels, exacerbate clinical symptoms, and delay the recovery of testosterone levels after discontinuationRelugolix is an oral GnRH receptor antagonist that binds and blocks GnRH receptors in the pituitary front already, reducing the release of progesterone-producing hormones (LH) and follicle stimulators (FSH), thereby reducing estrogen levels produced by the female ovaries and the production of male testosteroneMyovant Sciences is developing relugolix monodothel tablets for advanced prostate cancer and relugolix combination tablets for uterine fibroidsPreviously, the relugolix combination tablet has achieved positive results in Phase 3 clinical trials for the treatment of uterine fibroidsA map of the mechanisms of the role of The relugolix (photo: Myovant Sciences)1,100 prostate cancer patients participated in the Phase 3 clinical trial called HEROThe results showed that 96.7% of patients treated with relugolix continued to suppress their testosterone to anexoric level of 50 ng/dL, reaching the main end of the trialPatients in the treatment group significantly outperformed patients treated with acetate and acetate in the active control group in terms of rapid suppression of testosterone and reduced prostate-specific antigen (PSA) levels, reaching the critical secondary endpoint of the trialin addition,, the effect of relugolix on continuous suppression of testosterone in patients over a 48-week severance was not as good as that of acetate, at 96.7% and 88.8%, respectively, compared to acetateThe results of the trial showed that the patient received relugolix treatment and did not experience a brief increase in testosterone levels, and within 90 days of discontinuation, the average testosterone level soutcomed returned to normal" positive results from the HERO study demonstrate that relugolix has a unique therapeutic effect compared to bright crereWe hope to be able to submit our application for a new drug to the FDA as soon as possible," said Dr Lynn Seely, President and CEO of Myovant Sciences References: , Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer, Retrieved November 19, 2019, https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-announces-97-response-rate-positive-phase-3